ABEO
Price
$5.39
Change
+$0.17 (+3.26%)
Updated
Apr 24 closing price
Capitalization
263.03M
13 days until earnings call
SCPH
Price
$2.50
Change
-$0.10 (-3.85%)
Updated
Apr 24 closing price
Capitalization
125.71M
25 days until earnings call
Ad is loading...

ABEO vs SCPH

Header iconABEO vs SCPH Comparison
Open Charts ABEO vs SCPHBanner chart's image
Abeona Therapeutics
Price$5.39
Change+$0.17 (+3.26%)
Volume$1.35M
Capitalization263.03M
scPharmaceuticals
Price$2.50
Change-$0.10 (-3.85%)
Volume$229.9K
Capitalization125.71M
ABEO vs SCPH Comparison Chart
Loading...
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABEO vs. SCPH commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABEO is a Buy and SCPH is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (ABEO: $5.39 vs. SCPH: $2.50)
Brand notoriety: ABEO and SCPH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABEO: 210% vs. SCPH: 45%
Market capitalization -- ABEO: $263.03M vs. SCPH: $125.71M
ABEO [@Biotechnology] is valued at $263.03M. SCPH’s [@Biotechnology] market capitalization is $125.71M. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.16B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABEO’s FA Score shows that 0 FA rating(s) are green whileSCPH’s FA Score has 0 green FA rating(s).

  • ABEO’s FA Score: 0 green, 5 red.
  • SCPH’s FA Score: 0 green, 5 red.
According to our system of comparison, ABEO is a better buy in the long-term than SCPH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABEO’s TA Score shows that 6 TA indicator(s) are bullish while SCPH’s TA Score has 5 bullish TA indicator(s).

  • ABEO’s TA Score: 6 bullish, 3 bearish.
  • SCPH’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, ABEO is a better buy in the short-term than SCPH.

Price Growth

ABEO (@Biotechnology) experienced а +11.36% price change this week, while SCPH (@Biotechnology) price change was -2.72% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.06%. For the same industry, the average monthly price growth was -5.30%, and the average quarterly price growth was -11.62%.

Reported Earning Dates

ABEO is expected to report earnings on Aug 18, 2025.

SCPH is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+8.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABEO($263M) has a higher market cap than SCPH($126M). ABEO YTD gains are higher at: -3.232 vs. SCPH (-29.379). ABEO has higher annual earnings (EBITDA): -64.95M vs. SCPH (-71.31M). ABEO has more cash in the bank: 110M vs. SCPH (91.5M). ABEO has less debt than SCPH: ABEO (23.1M) vs SCPH (52.5M). SCPH has higher revenues than ABEO: SCPH (30.3M) vs ABEO (0).
ABEOSCPHABEO / SCPH
Capitalization263M126M209%
EBITDA-64.95M-71.31M91%
Gain YTD-3.232-29.37911%
P/E RatioN/AN/A-
Revenue030.3M-
Total Cash110M91.5M120%
Total Debt23.1M52.5M44%
FUNDAMENTALS RATINGS
ABEO vs SCPH: Fundamental Ratings
ABEO
SCPH
OUTLOOK RATING
1..100
1810
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
67
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
4787
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ABEO's Valuation (60) in the Pharmaceuticals Generic industry is in the same range as SCPH (67) in the Pharmaceuticals Major industry. This means that ABEO’s stock grew similarly to SCPH’s over the last 12 months.

ABEO's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as SCPH (100) in the Pharmaceuticals Major industry. This means that ABEO’s stock grew similarly to SCPH’s over the last 12 months.

SCPH's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as ABEO (98) in the Pharmaceuticals Generic industry. This means that SCPH’s stock grew similarly to ABEO’s over the last 12 months.

ABEO's Price Growth Rating (47) in the Pharmaceuticals Generic industry is somewhat better than the same rating for SCPH (87) in the Pharmaceuticals Major industry. This means that ABEO’s stock grew somewhat faster than SCPH’s over the last 12 months.

ABEO's P/E Growth Rating (100) in the Pharmaceuticals Generic industry is in the same range as SCPH (100) in the Pharmaceuticals Major industry. This means that ABEO’s stock grew similarly to SCPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABEOSCPH
RSI
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
70%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
Momentum
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
82%
MACD
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 11 days ago
77%
Declines
ODDS (%)
Bearish Trend 9 days ago
88%
Bearish Trend 1 day ago
85%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
70%
Aroon
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
89%
View a ticker or compare two or three
Ad is loading...
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ITHSX47.57N/A
N/A
Hartford Capital Appreciation R4
MUESX29.94N/A
N/A
MFS Blended Research Core Equity R2
LMGAX22.04N/A
N/A
Lord Abbett Growth Opportunities A
NCBVX18.24N/A
N/A
PGIM Quant Solutions Mid-Cap Val C
PQJCX12.28N/A
N/A
PGIM Jennison Small-Cap Core Equity R6

ABEO and

Correlation & Price change

A.I.dvisor tells us that ABEO and RZLT have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ABEO and RZLT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABEO
1D Price
Change %
ABEO100%
+3.26%
RZLT - ABEO
31%
Poorly correlated
-0.25%
AXON - ABEO
31%
Poorly correlated
+2.39%
MLEC - ABEO
29%
Poorly correlated
-5.13%
SCPH - ABEO
29%
Poorly correlated
-3.85%
XNCR - ABEO
29%
Poorly correlated
-0.28%
More

SCPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, SCPH has been loosely correlated with BEAM. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if SCPH jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCPH
1D Price
Change %
SCPH100%
-3.85%
BEAM - SCPH
44%
Loosely correlated
+1.51%
ABCL - SCPH
43%
Loosely correlated
+2.77%
XERS - SCPH
41%
Loosely correlated
+3.63%
IMNM - SCPH
41%
Loosely correlated
+0.24%
AURA - SCPH
41%
Loosely correlated
-4.17%
More